Lipika Goyal
MD, MPhil
Associate Professor of Medicine
👥Biography 个人简介
Lipika Goyal at Stanford is a leading expert in FGFR2-altered cholangiocarcinoma, having conducted pivotal work on pemigatinib, infigratinib, and futibatinib in FGFR2 fusion-positive intrahepatic cholangiocarcinoma. Her laboratory has defined mechanisms of acquired resistance to FGFR inhibitors in CCA including FGFR2 kinase domain mutations, and she has evaluated next-generation FGFR inhibitors to overcome resistance. She led or co-led FIGHT-202 and FOENIX-CCA2 registration trials. Her work has made FGFR2 testing an essential component of iCCA molecular profiling.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Lipika Goyal 的研究动态
Follow Lipika Goyal's research updates
留下邮箱，当我们发布与 Lipika Goyal（Stanford University）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment